Related references
Note: Only part of the references are listed.Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats
A. J. Rudinsky et al.
DOMESTIC ANIMAL ENDOCRINOLOGY (2015)
Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats
M. J. Hall et al.
DOMESTIC ANIMAL ENDOCRINOLOGY (2015)
Effects of the glucagon-like peptide-1 (GLP-1) analogues exenatide, exenatide extended-release, and of the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism in healthy cats
I. Padrutt et al.
RESEARCH IN VETERINARY SCIENCE (2015)
Stability of glucagon-like peptide 1 and glucagon in human plasma
Nicolai J. Wewer Albrechtsen et al.
ENDOCRINE CONNECTIONS (2015)
Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?
Nicolai J. Wewer Albrechtsen et al.
DIABETOLOGIA (2014)
Obesity and sex influence insulin resistance and total and multimer adiponectin levels in adult neutered domestic shorthair client-owned cats
C. R. Bjornvad et al.
DOMESTIC ANIMAL ENDOCRINOLOGY (2014)
ANIMAL MODELS OF DISEASE Classification and etiology of diabetes in dogs and cats
Richard W. Nelson et al.
JOURNAL OF ENDOCRINOLOGY (2014)
2014 AAHA Weight Management Guidelines for Dogs and Cats
Dawn Brooks et al.
JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION (2014)
Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies
Ling Li et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs
L. Simonsen et al.
REGULATORY PEPTIDES (2013)
Glucagon and Type 2 Diabetes: the Return of the Alpha Cell
Asger Lund et al.
CURRENT DIABETES REPORTS (2012)
Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
Jody Dushay et al.
DIABETES CARE (2012)
Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment
M. S. Fineman et al.
DIABETES OBESITY & METABOLISM (2012)
Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity
F. K. Knop et al.
DIABETES OBESITY & METABOLISM (2012)
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
A. Astrup et al.
INTERNATIONAL JOURNAL OF OBESITY (2012)
Analytical performance of commercially-available assays for feline insulin-like growth factor 1 (IGF-1), adiponectin and ghrelin measurements
Asta Tvarijonaviciute et al.
JOURNAL OF FELINE MEDICINE AND SURGERY (2012)
Exenatide as a Weight-Loss Therapy in Extreme Pediatric Obesity: A Randomized, Controlled Pilot Study
Aaron S. Kelly et al.
OBESITY (2012)
The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats
C. Gilor et al.
DOMESTIC ANIMAL ENDOCRINOLOGY (2011)
Prevalence and risk factors for feline obesity in a first opinion practice in Glasgow, Scotland
Emily A. Courcier et al.
JOURNAL OF FELINE MEDICINE AND SURGERY (2010)
The impact of obesity, sex, and diet on hepatic glucose production in cats
Saskia Kley et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2009)
Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
Thomas J. Moretto et al.
CLINICAL THERAPEUTICS (2008)
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
Ralph A. DeFronzo et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Treatment of 46 cats with porcine lente insulin - a prospective, multicentre study
Laurence Michiels et al.
JOURNAL OF FELINE MEDICINE AND SURGERY (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
The physiology of glucagon-like peptide 1
Jens Juul Holst
PHYSIOLOGICAL REVIEWS (2007)
Insulin sensitivity and β-cell function in healthy cats:: Assessment with the use of the hyperglycemic glucose clamp
L. I. Slingerland et al.
HORMONE AND METABOLIC RESEARCH (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Synthetic exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
OG Kolterman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Plasma leptin concentrations are independently associated with insulin sensitivity in lean and overweight cats
DJ Appleton et al.
JOURNAL OF FELINE MEDICINE AND SURGERY (2002)
Plasma leptin concentrations in cats: reference range, effect of weight gain and relationship with adiposity as measured by dual energy X-ray absorptiometry
D. J. Appleton et al.
JOURNAL OF FELINE MEDICINE AND SURGERY (2000)
Relationship between serum leptin immunoreactivity and body fat mass as estimated by use of a novel gas-phase Fourier transform infrared spectroscopy deuterium dilution method in cats
RC Backus et al.
AMERICAN JOURNAL OF VETERINARY RESEARCH (2000)
Share Paper
